1st Edition

Rapid Revision in Clinical Pharmacology




ISBN 9781857757958
Published April 26, 2008 by CRC Press
232 Pages

USD $42.95

Prices & shipping based on shipping country


Preview

Book Description

This book addresses the five core components of an investment appraisal; strategic, economic, commercial, financial and project management. It provides managers and policy makers in healthcare, government and private sector organisations with a tried and tested decision making tool and supporting guidance to improve capital investment decisions. It is a practical guide that includes numerous examples from the health service as well as lessons learnt from other public sector areas where best practice has been demonstrated. Comprehensively illustrated with case studies, checklists and templates to aid decision making, it offers practical, evidence-based guidance, clear summaries and pointers to accessing further information.

Table of Contents

Pharmacokinetics. Pharmacodynamics. Clinical trials. Receptor types. Autonomic nervous system 1. Autonomic nervous system 2. Autonomic nervous system 3. Neuromuscular junction. Myasthenia. 5-HT. Eiconasoids. Peptides and proteins as drugs. Systems targeted by drugs. Diuretics. Drugs and the heart I: heart failure. Drugs and the heart II: myocardial infarction (heart attack). Drugs and the heart III: antidysrhythmic drugs. Drugs and the heart IV: angina pectoris. Drugs and the heart V: antiplatelet drugs. Anticoagulants I: heparin. Anticoagulants II: oral anticoagulants. Fibrinolytic and antifibrinolytic drugs. Hypertension I: introduction. Hypertension II: treatment. Inflammation I: introduction. Inflammation II: NSAIDS. Inflammation III: steroidal anti-inflammatory drugs. Inflammation IV: disease-modifying antirheumatic drugs (DMARDS). Inflammation V: gout, scleroderma and raynaud’s phenomenon. Paracetamol. Opioid analgesics. Local anaesthetics. General anaesthetics. Parkinson’s disease. Epilepsy. Alzheimer’s disease. Antidepressant drugs. Anxiolytic drugs. Anti-infective agents. Malignancy.

...
View More